The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
Open accessAbstract
Interleukin (IL)-6, a cytokine featuring redundancy and pleiotropic activity, contributes to host defense against acute environmental stress, while dysregulated persistent IL-6 production has been demonstrated to play a pathological role in various autoimmune and chronic inflammatory diseases. Targeting IL-6 is thus a rational approach to the treatment of these diseases. Indeed, clinical trials of tocilizumab, a humanized anti-IL-6 receptor antibody have verified its efficacy and tolerable safety for patients with rheumatoid arthritis, Castleman's disease and systemic juvenile idiopathic arthritis, resulting in approval of this innovative biologic for treatment of these diseases. Moreover, a considerable number of case reports and pilot studies of off-label use of tocilizumab point to the beneficial effects of tocilizumab for a variety of other phenotypically different autoimmune and chronic inflammatory diseases. Elucidation of the source of IL-6 and of mechanisms through which IL-6 production is dysregulated can thus be expected to lead to clarification of the pathogenesis of various diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394 · cited 1×
“In the early phase of infectious inflammation, IL-6 is produced by monocytes and macrophages immediately after the stimulation of Toll-like receptors (TLRs) with distinct pathogen-associated molecular patterns (PAMPs) [5].”
BackgroundKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Continuously high levels of hepcidin induced by IL-6 block iron transporter ferroportin 1 in macrophages, hepatocytes, and gut epithelial cells and lead to hypoferremia and anemia of chronic inflammation [11], whereas long-term high levels of SAA result in amyloid A amyloidosis [12].”
BackgroundHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 2×
“Interleukin-6 (IL-6), initially designated as a B cell differentiation factor [1], is a representative cytokine featuring redundancy and pleiotropic activity [2-4].”
BackgroundSelf-citationAutocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citation(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., & Akira, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10193 · Cited by 959
Self-citationGenovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Self-citation
Cited by
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Self-citationMast cells as sources of cytokines, chemokines, and growth factors
Mukai, K., Tsai, M., Saito, H., & Galli, S. J. (2018) · Immunological Reviews · doi:10.1111/imr.12634 · Cited by 682
Goldburg, S. R., Strober, B. E., & Payette, M. J. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.090 · Cited by 486
Watt, D. G., Horgan, P. G., & McMillan, D. C. (2015) · Surgery · doi:10.1016/j.surg.2014.09.009 · Cited by 385
Choi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14228 · Cited by 355
Jordan, S. C., Choi, J., Kim, I., Wu, G., Toyoda, M., Shin, B., & Vo, A. (2017) · Transplantation · doi:10.1097/tp.0000000000001452 · Cited by 260
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
Fujihara, K., Bennett, J. L., de Seze, J., Haramura, M., Kleiter, I., Weinshenker, B. G., Kang, D., Mughal, T., & Yamamura, T. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000841 · Cited by 253
Gupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
Immune Dysregulation in Children With Down Syndrome
Huggard, D., Doherty, D. G., & Molloy, E. J. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00073 · Cited by 144
Increased systemic inflammation in children with Down syndrome
Huggard, D., Kelly, L., Ryan, E., McGrane, F., Lagan, N., Roche, E., Balfe, J., Leahy, T. R., Franklin, O., Doherty, D. G., et al. (2020) · Cytokine · doi:10.1016/j.cyto.2019.154938 · Cited by 94
Yang, R., Lirussi, D., Thornton, T. M., Jelley-Gibbs, D. M., Diehl, S. A., Case, L. K., Madesh, M., Taatjes, D. J., Teuscher, C., Haynes, L., et al. (2015) · eLife · doi:10.7554/elife.06376 · Cited by 91
Oncostatin M and its role in fibrosis
Stawski, L., & Trojanowska, M. (2019) · Connective Tissue Research · doi:10.1080/03008207.2018.1500558 · Cited by 86
Hao, Y., Jing, H., Bi, Q., Zhang, J., Qin, L., & Yang, P. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.052 · Cited by 38
Metadata
- Authors
- Tanaka, T., & Kishimoto, T.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2012
- Volume
- 8
- Issue
- 9
- Pages
- 1227-1236
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2154984288
- Cited by
- 244
- References
- 17
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.